Navigation Links
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
Date:5/18/2009

OXFORD, England, May 18 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures' transactions experience in the healthcare and investment business sectors.

Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials.

Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program.

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors."

InDex will be presenting Phase II data at BIO on Wednesday 20th May. See also InDex's Press Release released today: http://www.indexpharmab.com/images/pdf/kappaproctmay2009.pdf

Visit PharmaVentures during BIO at booths 4209 & 4211 for further information on this and other licensing opportunities.

    For enquiries abo
'/>"/>
SOURCE PharmaVentures
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Standard & Poors Announces Changes to U.S. Index
2. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
3. Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
4. Chindex International, Inc. Announces May Conference Participation
5. ICW Master Patient Index Passes HITSP Certification and IHE Tests
6. SXC Health Solutions Added to S&P/TSX Composite Index
7. HCD Research and Muhlenberg College Will Use an Index to Monitor Physicians and Consumers Perceptions of Health Care Reform
8. MIB Life Index Reports North American Life Insurance Activity up 1.1% in February
9. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
10. Molecular Oncology accepted into Thomson Reuters index
11. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey has ... They’ve treated over 40,000 patients while carrying out their ... to the Paramus area. , For 2015, the practice ... of top-notch board certified physicians: Christine Milosis MD, Sandra Ugras ... doctors will work tirelessly to carry out The Doctor’s ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
(Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
(Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... researchers have identified an unexpected molecular marker that ... to chemotherapy. Triple-negative breast cancers --which do ... progesterone receptor and do not have Her2/neu overexpression ... of the disease and cannot be treated with ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... early stage prostate cancer, those who have the prostate gland ... a "watchful waiting" approach, according to a new long-term study ... to be practice-changing, said Dr. Richard E. Greenberg, chief of ...
... Gardner HealthDay Reporter , WEDNESDAY, May 4 ... was able to rectify ventricular fibrillation, a severely abnormal ... none experienced sudden death, according to new research. ... is already approved in Europe and is undergoing review ...
... May issue of the journal Health Affairs , Mount ... of toxic chemicals and air pollutants in the environment, and ... also those already on the market. Leonardo Trasande, ... Sinai School of Medicine, analyzed the costs of conditions ...
... MOINES, Iowa, May 4, 2011 The Donald Danforth Plant ... from the Howard G. Buffett Foundation to bring healthier sorghum ... help fund the completion of the development of biofortified sorghum, ... upon sorghum as their staple diet. DuPont business Pioneer ...
... Translational Genomics Research Institute (TGen) has licensed its first ... modifying the actions of proteins. Today,s announcement is ... laboratory discoveries more rapidly into therapeutics that can immediately ... drug, ONCO-101, is being licensed to Syracuse, N.Y.-based Oncoholdings ...
Cached Medicine News:Health News:Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 3Health News:New Defibrillator Shows Promise in Small Study 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 3Health News:Grant funds next phase in bringing healthier sorghum closer to underserved communities 2Health News:TGen licenses first drug for patient use in clinical care 2
(Date:12/19/2014)... Fla. , Dec. 19, 2014 Breckenridge ... a multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... MSN expect to commercialize several new ANDAs.  Under the ... supply the products exclusively to Breckenridge for the U.S. ... under its label.  Breckenridge and MSN have agreed to ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... 2007 - Geron,Corporation (Nasdaq:GERN) today announced the ... company's human,embryonic stem cell (hESC)-based therapeutic for ... direct attack by the human immune,system., Presented ... Federation of,Clinical Immunology Societies meeting in San ...
... BETHESDA, Md., June 11, 2007--New research supported ... of Arthritis and,Musculoskeletal and Skin Diseases (NIAMS) ... which is used for certain,types of seizures, ... pain and,other symptoms associated with the common, ...
Cached Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3
... to detect sequences of the following ... 2 and 3; influenza virus A ... A and B. Laboratories may ... tests., *Analyte Specific Reagents. ...
... molecular labs a more advanced alternative for ... MGB technology, combined with post-PCR dissociation melt ... provide molecular labs more powerful tools for ... or genetic mutations associated with disease, as ...
... NGEN-brand ASRs* are specifically designed for ... with two-color fluorescence detection systems. The ... the detection of mutations associated with ... as well as reagents for the ...
... offers reagents for the detection of ... the G1691A mutation on the Factor ... mutation on the Prothrombin gene. Laboratories ... homebrew tests.,, *Analyte Specific ...
Medicine Products: